About: Detection of blood‐transmissible agents: can screening be miniaturized?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Detection of blood‐transmissible agents: can screening be miniaturized? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Detection of blood‐transmissible agents: can screening be miniaturized?
Creator	Coste, Joliette Fournier-Wirth, Chantal Jaffrezic-Renault, Nicole
Source	PMC
abstract	Transfusion safety relating to blood‐transmissible agents is a major public health concern, particularly when faced with the continuing emergence of new infectious agents. These include new viruses appearing alongside other known reemerging viruses (West Nile virus, Chikungunya) as well as new strains of bacteria and parasites (Plasmodium falciparum, Trypanosoma cruzi) and finally pathologic prion protein (variant Creutzfeldt‐Jakob disease). Genomic mutations of known viruses (hepatitis B virus, hepatitis C virus, human immunodeficiency virus) can also be at the origin of variants susceptible to escaping detection by diagnostic tests. New technologies that would allow the simultaneous detection of several blood‐transmissible agents are now needed for the development and improvement of screening strategies. DNA microarrays have been developed for use in immunohematology laboratories for blood group genotyping. Their application in the detection of infectious agents, however, has been hindered by additional technological hurdles. For instance, the variability among and within genomes of interest complicate target amplification and multiplex analysis. Advances in biosensor technologies based on alternative detection strategies have offered new perspectives on pathogen detection; however, whether they are adaptable to diagnostic applications testing biologic fluids is under debate. Elsewhere, current nanotechnologies now offer new tools to improve the sample preparation, target capture, and detection steps. Second‐generation devices combining micro‐ and nanotechnologies have brought us one step closer to the potential development of innovative and multiplexed approaches applicable to the screening of blood for transmissible agents.
has issue date	2010-06-07(xsd:dateTime)
bibo:doi	10.1111/j.1537-2995.2010.02678.x
bibo:pmid	20546202
has license	no-cc
sha1sum (hex)	20ce33fe1fadecc703d1b8974cf15fb518ca254b
schema:url	https://doi.org/10.1111/j.1537-2995.2010.02678.x
resource representing a document's title	Detection of blood‐transmissible agents: can screening be miniaturized?
has PubMed Central identifier	PMC7182305
has PubMed identifier	20546202
schema:publication	Transfusion
resource representing a document's body	covid:20ce33fe1fadecc703d1b8974cf15fb518ca254b#body_text
is schema:about of	named entity 'SPR' named entity 'par' named entity 'R&D' named entity 'surface plasmon resonance' named entity 'prostate-specific antigen' named entity 'SANG' named entity 'quantum dot' named entity 'SPR' named entity 'PSA' named entity 'PAR' named entity 'resonance' named entity 'surface plasmon' named entity 'prostate-specific antigen' named entity 'Transfusion' named entity 'quantum dot' named entity 'Detection' named entity '2032' named entity 'PSA' named entity 'Pyrénées' named entity 'QUANTUM DOT' named entity 'SURFACE PLASMON RESONANCE' named entity 'ABBREVIATIONS' named entity 'PROSTATE-SPECIFIC ANTIGEN' named entity 'DETECTION' named entity 'miniaturized' named entity 'SPR' named entity '28S' named entity 'PSA' named entity 'TRANSFUSION' named entity '2032' named entity 'BLOOD' named entity '2678' named entity 'SCREENING' named entity 'I E'
is part of of	Transfusion safety relating to blood‐transmissible agents is a major public health concern, particularly when faced with the continuing emergence of new infectious agents. These include new viruses appearing alongside other known reemerging viruses (West Nile virus, Chikungunya) as well as new strains of bacteria and parasites (Plasmodium falciparum, Trypanosoma cruzi) and finally pathologic prion protein (variant Creutzfeldt‐Jakob disease). Genomic mutations of known viruses (hepatitis B virus, hepatitis C virus, human immunodeficiency virus) can also be at the origin of variants susceptible to escaping detection by diagnostic tests. New technologies that would allow the simultaneous detection of several blood‐transmissible agents are now needed for the development and improvement of screening strategies. DNA microarrays have been developed for use in immunohematology laboratories for blood group genotyping. Their application in the detection of infectious agents, however, has been hindered by additional technological hurdles. For instance, the variability among and within genomes of interest complicate target amplification and multiplex analysis. Advances in biosensor technologies based on alternative detection strategies have offered new perspectives on pathogen detection; however, whether they are adaptable to diagnostic applications testing biologic fluids is under debate. Elsewhere, current nanotechnologies now offer new tools to improve the sample preparation, target capture, and detection steps. Second‐generation devices combining micro‐ and nanotechnologies have brought us one step closer to the potential development of innovative and multiplexed approaches applicable to the screening of blood for transmissible agents. Detection of blood‐transmissible agents: can screening be miniaturized? covid:20ce33fe1fadecc703d1b8974cf15fb518ca254b#body_text

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software